EMA Authorised: Tyruko (natalizumab) — Sandoz GmbH

View source ↗

Summary

The European Medicines Agency authorised Tyruko, a natalizumab biosimilar by Sandoz GmbH, for treatment of multiple sclerosis including the relapsing-remitting …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• TYRUKO (natalizumab-sztn)

Snippet

Status: Authorised. Therapeutic area: Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis. MAH: Sandoz GmbH. Decision date: 02/03/2026